Suboxone · DIN 02502313 · 2 mg & 0.5 mg · Soluble Film
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Free naloxone kits in Ontario: no prescription or health card needed; free kits at participating pharmacies and community sites
Free naloxone kits: eligibility and access
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Suboxone · DIN 02502313
Manufacturer: Indivior UK Limited; listing date 2024-05-31
Health Canada: Marketed since 2021-01-20 · brand SUBOXONE · ATC N07BC51 BUPRENORPHINE, COMBINATIONS, N07BC51 BUPRENORPHINE, COMBINATIONS · form Film (soluble) · route Buccal, Sublingual · ingredients BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 2 MG, NALOXONE (NALOXONE HYDROCHLORIDE) 0.5 MG · company Indivior uk limited · schedule Narcotics (cdsa i)
DIN 02502313: Suboxone
Raw flags: sec3=Y
Item: 280812032; group id 415; item number 1023; lccId None; manufacturer id IND
Source form: Soluble Film; strength: 2mg & 0.5mg
Recorded listing: General benefit
Source prices (unrounded): $2.6700; ministry $2.6700
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02502313
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99189
Shortage status: resolved shortage (ended April 28, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02502313
Shortage record checked October 6, 2026
Other products in the same Health Canada class (N07BC): coverage varies; not interchangeable
Buprenorphine (Sublocade): general benefit
Buprenorphine (Probuphine): limited Use 578
Other drugs in the same formulary class (28:08:12 Opiate Partial Agonists) and how they are covered
Matched class: 28:08:12 Opiate Partial Agonists
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: BUPRENORPHINE
28:08:12 Opiate Partial Agonists
1 INDICATIONS
SUBOXONE® (buprenorphine and naloxone) is indicated for:
• substitution treatment in adults with problematic opioid drug dependence.
1.1 Pediatrics
Pediatrics (<18 years of age): Based on the data submitted and reviewed by Health Canada, the
safety and efficacy of SUBOXONE in pediatric patients has not been established; therefore,
Health Canada has not authorized an indication for pediatric use.
1.2 Geriatrics
Geriatrics (> 65 years of age): The safety and efficacy of SUBOXONE have not been established
in adults over 65 years of age.
In general, dose selection for an elderly patient should be cautious, usually starting at the low
end of the dosing range, reflecting the greater frequency of decreased hepatic, renal,
respiratory or cardiac function, concomitant disease or other drug therapy.
https://pdf.hres.ca/dpd_pm/00069997.PDF
PM date: MAY 17, 2007
Source product: SUBOXONE; DIN 02295695; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.